VERA
Vera Therapeutics, Inc.
$33.32
-1.86
(-5.29%)
Mkt Cap
2.39B
Volume
2,193,423
52W Range
19.066-56.05
Sector
Healthcare
Beta
0.92
EPS (TTM)
-5.54
P/E Ratio
-10.87
Revenue (TTM)
0
Rev Growth (5Y)
N/A
EPS Growth (5Y)
N/A
Company Description
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.
Track Record
Showing latest 4 periods • Swipe for more
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (299.62M) | (152.15M) | (95.99M) | (89.06M) | (32.61M) | (53.41M) | (11.85M) |
| EPS | -4.66 | -2.75 | -2.25 | -3.35 | -2.43 | -14.40 | -3.46 |
| Free Cash Flow | (241.73M) | (135.65M) | (92.24M) | (67.66M) | (23.71M) | (34.91M) | (10.41M) |
| FCF / Share | -3.76 | -2.45 | -2.16 | -2.55 | -1.76 | -9.41 | -3.04 |
| Operating CF | (241.10M) | (134.68M) | (92.18M) | (67.60M) | (23.71M) | (34.81M) | (10.29M) |
| Total Assets | 734.73M | 655.68M | 175.55M | 131.44M | 83.75M | 54.55M | 5.38M |
| Total Debt | 77.31M | 54.64M | 53.71M | 31.29M | 4.92M | 2,000 | 132,000 |
| Cash & Equiv | 354.73M | 92.65M | 45.68M | 43.46M | 79.67M | 53.65M | 3.19M |
| Book Value | 604.52M | 577.15M | 101.69M | 76.91M | 69.59M | (89.35M) | (36.55M) |
| Return on Equity | -0.50 | -0.26 | -0.94 | -1.16 | -0.47 | N/A | N/A |
| Metric | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | (121.03M) | (91.10M) | (80.29M) | (76.53M) | (51.69M) | (43.42M) | (46.63M) | (33.71M) | (28.38M) | (25.66M) | (20.10M) | (20.16M) |
| EPS | -1.69 | -1.39 | -1.26 | -1.20 | -0.81 | -0.85 | -0.85 | -0.62 | -0.56 | -0.58 | -0.45 | -0.46 |
| Free Cash Flow | (106.67M) | (70.10M) | (62.04M) | (55.01M) | (54.59M) | (39.83M) | (61.99M) | (24.87M) | (33.83M) | (25.21M) | (22.97M) | (17.77M) |
| FCF / Share | -1.49 | -1.09 | -0.97 | -0.86 | -0.86 | -0.73 | -1.13 | -0.45 | -0.66 | -0.57 | -0.52 | -0.40 |
| Operating CF | (106.50M) | (69.99M) | (61.91M) | (54.80M) | (54.41M) | (39.18M) | (36.88M) | (24.78M) | (33.83M) | (25.14M) | (22.97M) | (17.77M) |
| Total Assets | 621.74M | 734.73M | 517.50M | 578.53M | 610.17M | 655.68M | 368.56M | 397.29M | 419.36M | 175.55M | 175.62M | 195.18M |
| Total Debt | 75.03M | 77.31M | 77.22M | 77.55M | 54.47M | 54.64M | 54.91M | 52.83M | 53.26M | 53.71M | 29.52M | 30.09M |
| Cash & Equiv | 114.35M | 354.73M | 57.77M | 49.12M | 55.09M | 92.65M | 27.26M | 25.09M | 69.11M | 45.68M | 27.44M | 33.89M |
| Book Value | 499.70M | 604.52M | 398.88M | 468.28M | 535.00M | 577.15M | 289.06M | 327.87M | 353.54M | 101.69M | 123.71M | 140.52M |
| Return on Equity | -0.24 | -0.15 | -0.20 | -0.16 | -0.10 | -0.08 | -0.16 | -0.10 | -0.08 | -0.25 | -0.16 | -0.14 |
VERA News
Vera Therapeutics Wins FDA Approval for TRUTAKNA in IgA Nephropathy, Sets Launch
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Vera Therapeutics Announces Appointment of Nancy Boman as Chief Regulatory Officer and Planned Retirement of William Turner
Vera Therapeutics, Inc. (VERA) Discusses Accelerated FDA Approval of TRUTAKNA for IgA Nephropathy Transcript
US FDA approves Vera's kidney disease drug
Vera Therapeutics Receives FDA Accelerated Approval for TRUTAKNA™ for Adult Patients with Primary IgA Nephropathy
What's Going on with Vera Therapeutics Stock on Monday?
3 Biotech Firms With Major Potential Catalysts in the Coming Months
3 Biotech Firms With Major Potential Catalysts in the Coming Months
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)